

## High-Risk, Early Breast Cancer: Clinical Features and the Risk of Recurrence for HR+/HER2- Disease

## Incidence of HR+/HER2- breast cancer


Most patients with early breast cancer (EBC) have hormone receptor–positive (HR+)/HER2-negative (HER2-) disease<sup>1</sup>

4.6% HR-/HER2+ Breast Cancer Molecular Subtypes at Diagnosis<sup>1</sup> 10.3% HR+/HER2+ 12.2% TNBC

## Some clinical features of high-risk disease

Patients with **HR+/HER2- breast cancer** at high-risk of recurrence may present with<sup>5</sup>








## **About 70%** of EBC is HR+/HER2-

#### or 1-3 positive ALNs with




**EBC** has no spread detected beyond the breasts and lymph nodes in and around the breasts and has gone only as far as the lymph nodes in the armpit(s).<sup>2</sup> Some patients with EBC have cancer cells that are **more aggressive and more likely to grow and spread quickly**, which means there is a **higher risk of the cancer recurring**<sup>3,4</sup>



### **Recurrence rates**

~30% of patients with high-risk, HR+/HER2-

EBC may experience recurrence, often with distant metastases<sup>5</sup>




About 3 in 10 patients with high-risk, HR+/HER2- EBC will experience disease recurrence within 5 years<sup>5</sup>

Compared with grade 1 disease, patients with grade 3 tumors have a **3.9x increased risk of distant recurrence** over 10 years<sup>6</sup> Similarly, patients with stage III disease are at a **2.0x increased risk of** recurrence over 10 years compared to patients with stage I disease<sup>7</sup>

As health care providers, it is important to recognize these features associated with a higher risk of recurrence

## Sites of recurrence<sup>8,9</sup>



Most disease recurrence occurs at distant sites. Common sites of distant recurrence include the bone, liver, lungs, and brain. Although local and regional recurrences are treated with curative intent, **distant recurrences remain largely incurable but are treatable** 

Location and incidence of recurrence <a>

Distant recurrence: 60%-70% | Locoregional recurrence: 20%-40%


Howlader N, et al. *J Natl Cancer Inst.* 2014;106(5):dju055.
https://www.cancer.gov/publications/dictionaries/cancer-terms/def/early-stage-breast-cancer. (Accessed March 3, 2023).
https://www.cancer.gov/publications/dictionaries/cancer-terms/def/recurrent-cancer. (Accessed March 3, 2023).
https://www.cancer.gov/publications/dictionaries/cancer-terms/def/aggressive. (Accessed March 3, 2023).
Sheffield KM, et al. *Future Oncol.* 2022;18(21): 2667-2682.
Holleczek B, et al. *BMC Cancer.* 2019;19(1):520.
Cheng L, et al. *Cancer Epidemiology Biomarkers & Prevention.* 2012;21(5):800-809.
Gerber B, et al. *Dtsch Arztebl Int.* 2010;107(6):85-89.
Cardoso F, et al. *Ann Oncol.* 2020;31(12):1623-1649.

VV-MED-135752 02/2023 © 2023 Lilly USA, LLC. All rights reserved.



## High-Risk, Early Breast Cancer: Clinical Features and the Risk of Recurrence for HR+/HER2- Disease

# EBC: Clinical and pathological factors associated with a higher risk of recurrence



Cheng L, et al. Cancer Epidemiol Biomarkers Prev. 2012;21(5):800-809.
Holleczek B, et al. BMC Cancer. 2019;19(1):520.
Pan H, et al. N Engl J Med. 2017;377(19):1836-1846.

VV-MED-135752 02/2023 © 2023 Lilly USA, LLC. All rights reserved.